Hyaluronidase Market By Product Type (Animal-Derived Hyaluronidase, Recombinant Human Hyaluronidase, Microbial-Derived Hyaluronidase); By Application (Drug Delivery, Dermatology and Aesthetics, Ophthalmology, Anesthesia, Oncology); By Formulation (Injectable Solutions, Lyophilized Powder, Co-formulated Injectables); By End User (Hospitals, Specialty Clinics, Aesthetic Clinics, Ambulatory Surgical Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Hyaluronidase Market: How Are Subcutaneous Therapies and Recombinant Enzymes Expanding Clinical Use? – (Updated On: 16th-Oct-2026)

The Global Hyaluronidase Market was estimated at USD 1.23 billion in 2025 and is projected to reach USD 2.25 billion by 2032, expanding at a CAGR of 9.0% during 2026–2032, according to Strategic Market Research.

 

Hyaluronidase is an injectable enzyme used to improve the absorption and distribution of medicines and fluids administered beneath the skin. Global adoption of hyaluronidase-based drug delivery is expanding. More than 1.3 million patients have received medicines using Halozyme's hyaluronidase-based technology, showing that it has become an established part of modern injectable drug treatment.

 

Hyaluronidase injections help the body absorb fluids and medicines more easily when they are given under the skin. According to the U.S. National Library of Medicine's DailyMed, Hylenex recombinant was studied in 51 children with mild to moderate dehydration, using 150 units of hyaluronidase to help deliver fluids. These results highlight the role of hyaluronidase in improving fluid administration and support its use in hospitals and other healthcare settings.

 

Recent FDA approvals are expanding the clinical applications of hyaluronidase-containing medicines. In September 2025, the FDA approved Merck's Keytruda Qlex for subcutaneous administration across eligible solid-tumor indications, supported by a clinical study involving 377 patients. In November 2025, the FDA approved Johnson & Johnson's Darzalex Faspro for adults with high-risk smoldering multiple myeloma, based on the 390-patient AQUILA trial. In July 2026, Keytruda Qlex received an additional approval for use with Padcev in eligible muscle-invasive bladder cancer patients, expanding its use in perioperative treatment.

 

Overall, the Hyaluronidase Market is evolving from conventional enzyme injections toward high-value pharmaceutical delivery platforms. Increasing adoption of subcutaneous cancer treatments, established applications in aesthetic corrections and anesthesia, and expanding regulatory approvals are strengthening its position across healthcare. Recombinant enzyme innovation and pharmaceutical integration are expected to remain central to market expansion through 2032.

 

Which Subsegments Are Leading the Hyaluronidase Market, and Where Are the Strongest Opportunities Emerging?

By Product Type: Recombinant Human Enzymes Lead Pharmaceutical Integration

Largest and Fastest-Growing Subsegment – Recombinant Human Hyaluronidase

Recombinant human hyaluronidase, particularly rHuPH20, is a laboratory-produced version of the natural human enzyme that temporarily breaks down hyaluronic acid within the extracellular matrix, facilitating the absorption and dispersion of subcutaneously administered medications. In the global Hyaluronidase Market, recombinant human hyaluronidase accounted for an estimated 65% market share, equivalent to USD 0.800 billion in 2025, and is projected to expand at a CAGR of 10.15% during 2026–2032, reflecting its growing application in subcutaneous biologic formulations and drug delivery.

 

By Application: Subcutaneous Drug Delivery Expands Clinical Utilization

Largest and Fastest-Growing Subsegment – Drug Delivery

Drug Delivery accounted for an estimated 48% of the global Hyaluronidase Market, equivalent to USD 0.590 billion in 2025, and is projected to expand at a CAGR of 9.79% during 2026–2032. Hyaluronidase facilitates drug administration by temporarily breaking down hyaluronic acid within the extracellular matrix, improving tissue permeability and accelerating the dispersion and absorption of co-administered medications. Its growing application in subcutaneous drug delivery, particularly for biologics and high-volume injectable therapies, supports wider clinical adoption and creates opportunities for advanced pharmaceutical formulations.

 

By Formulation: Co-formulated Injectables Support Larger Injection Volumes

Largest and Fastest-Growing Subsegment – Co-formulated Injectables

Co-formulated injectables combining biologics with hyaluronidase, particularly recombinant human PH20 (rHuPH20), facilitate subcutaneous drug administration by temporarily breaking down hyaluronic acid in the extracellular matrix, improving tissue permeability and enabling the delivery of larger injection volumes. Within the Hyaluronidase Market, co-formulated injectables accounted for an estimated 58% market share, equivalent to USD 0.713 billion in 2025, and are projected to expand at a CAGR of 10.46% during 2026–2032, supported by wider adoption of subcutaneous biologic formulations and simplified treatment administration.

 

By End User: Hospitals Lead as Aesthetic Clinics Expand Filler Correction

Largest Subsegment – Hospitals

Hospitals accounted for the largest share of the Hyaluronidase Market, representing an estimated 55% of the global market, equivalent to USD 0.677 billion in 2025, and are projected to expand at a CAGR of 8.67% during 2026–2032. Hyaluronidase plays an important role in hospital settings, particularly in managing intravenous drug extravasation, facilitating subcutaneous drug administration, and supporting emergency interventions. Its expanding clinical applications across emergency departments, oncology units, and specialized treatment facilities are strengthening hospital utilization and supporting sustained market growth.

Fastest-Growing Subsegment – Aesthetic Clinics

Aesthetic clinics play an increasingly important role in the Hyaluronidase Market, utilizing the enzyme to rapidly dissolve hyaluronic acid (HA) dermal fillers for emergency complication management, correction of overfilling, and elective facial contour adjustments. Aesthetic clinics accounted for an estimated 15% market share, equivalent to USD 0.185 billion in 2025, and are projected to register the fastest end-user CAGR of 9.97% during 2026–2032. Growing adoption of injectable cosmetic procedures and greater emphasis on filler safety are supporting hyaluronidase utilization across aesthetic practices.

 

By Geography: North American Adoption and Asia-Pacific Aesthetic Use Shape Expansion

Largest Regional Market – North America

North America maintains a leading position in the global Hyaluronidase Market, accounting for an estimated 42% market share, equivalent to USD 0.517 billion in 2025, with a projected CAGR of 8.58% during 2026–2032. The region’s strong position reflects the widespread clinical use of hyaluronidase in enhancing subcutaneous drug delivery, managing dermal filler complications, and supporting ophthalmic procedures. The United States remains a major contributor, supported by pharmaceutical innovation, expanding applications of hyaluronidase-enabled biologics, and continued investment in clinical research and therapeutic development.

Fastest-Growing Regional Market – Asia-Pacific

Asia-Pacific Hyaluronidase Market accounted for an estimated 23% of the global market, valued at USD 0.283 billion in 2025, and is projected to register the fastest regional CAGR of 10.98% during 2026–2032. Growth is primarily supported by the increasing popularity of aesthetic medicine, particularly hyaluronic acid (HA) dermal filler procedures across China, South Korea, Japan, and India. Rising utilization of hyaluronidase for correcting filler complications, dissolving unwanted fillers, and supporting injectable aesthetic treatments is strengthening its adoption across dermatology clinics and aesthetic treatment centers.

 

Which FDA-Approved Hyaluronidase Products Are Expanding Clinical and Pharmaceutical Applications?

Standalone FDA-Approved Hyaluronidase Products

• Hylenex (Recombinant Human Hyaluronidase) – Approved December 2, 2005: Developed using Halozyme Therapeutics' recombinant enzyme technology, Hylenex facilitates the absorption and dispersion of injected medications, supports hypodermoclysis, and serves as an adjunct in subcutaneous urography. Its approval established an important regulatory foundation for recombinant human hyaluronidase formulations.

• Amphadase (Bovine-Derived Hyaluronidase) – Approved October 26, 2004: Manufactured by Amphastar Pharmaceuticals, Amphadase is used to improve the dispersion and absorption of injected medications and supports subcutaneous fluid administration. Its applications include anesthesia and procedures requiring enhanced tissue distribution of injected substances.

• Vitrase (Ovine-Derived Hyaluronidase) – Approved May 2004: Vitrase is a preservative-free, sheep-derived hyaluronidase formulation used to increase the absorption and dispersion of injected drugs. Its approval established another animal-derived option for clinical applications requiring enzymatic spreading activity.

FDA-Approved Hyaluronidase Combination Medicines

• Darzalex Faspro (Daratumumab and Hyaluronidase) – Approved May 2020: Developed by Janssen, part of Johnson & Johnson, Darzalex Faspro enables subcutaneous administration of daratumumab for multiple myeloma. Subsequent FDA approvals expanded its treatment applications, including high-risk smoldering multiple myeloma in November 2025, strengthening hyaluronidase utilization in hematology.

• Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase) – Approved June 2020: Developed by Genentech, part of Roche, Phesgo combines HER2-targeted therapies with recombinant hyaluronidase for subcutaneous administration in eligible HER2-positive breast cancer patients. Its formulation reduces administration time compared with separate intravenous infusions.

• Vyvgart Hytrulo (Efgartigimod Alfa and Hyaluronidase) – Approved June 20, 2023: Developed by argenx, Vyvgart Hytrulo uses recombinant hyaluronidase to facilitate subcutaneous delivery for generalized myasthenia gravis. FDA approval for chronic inflammatory demyelinating polyneuropathy in June 2024 further expanded its clinical applications beyond the original indication.

• Tecentriq Hybreza (Atezolizumab and Hyaluronidase) – Approved September 12, 2024: Developed by Genentech, Tecentriq Hybreza provides a subcutaneous alternative to intravenous atezolizumab for approved adult cancer indications, including lung cancer and hepatocellular carcinoma. Its approval reinforces hyaluronidase's role in oncology treatment administration.

• Opdivo Qvantig (Nivolumab and Hyaluronidase) – Approved December 27, 2024: Developed by Bristol Myers Squibb, Opdivo Qvantig enables subcutaneous administration of nivolumab across specified solid-tumor indications. Its introduction creates additional opportunities for hyaluronidase in immuno-oncology formulations.

• Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa) – Approved September 19, 2025: Developed by Merck using Alteogen's ALT-B4 enzyme technology, Keytruda Qlex enables subcutaneous administration of pembrolizumab for approved solid-tumor indications. The approval highlights increasing competition between recombinant hyaluronidase platforms.

• Rybrevant Faspro (Amivantamab and Hyaluronidase) – Approved December 17, 2025: Developed by Janssen, Rybrevant Faspro provides a subcutaneous formulation of amivantamab for eligible patients with non-small cell lung cancer. Its approval extends hyaluronidase-enabled delivery into targeted lung cancer therapy.

 

Which Companies Are Shaping the Competitive Landscape of the Hyaluronidase Market?

Halozyme Therapeutics: Advancing ENHANZE Licensing and Recurring Royalty Revenue

Halozyme Therapeutics is a leading company in the global Hyaluronidase Market, particularly in recombinant human hyaluronidase technology and pharmaceutical drug delivery. Its proprietary ENHANZE technology, utilizing recombinant human hyaluronidase (rHuPH20), enables the conversion of intravenous biologic therapies into subcutaneous formulations. The technology is incorporated into commercially approved medicines, including Darzalex Faspro, Phesgo, and Vyvgart Hytrulo, strengthening Halozyme's position in oncology, immunology, and hematology applications.

According to Halozyme's 2025 financial results, the company generated USD 867.8 million in royalty revenue, increasing 52% from USD 571.0 million in 2024. Total company revenue reached USD 1.397 billion in 2025, representing a 38% annual increase. Halozyme reported 10 globally approved ENHANZE-enabled products, demonstrating the commercial adoption of its hyaluronidase platform. These results highlight the importance of recombinant enzyme licensing, pharmaceutical partnerships, and recurring royalties in the market. The reported company figures include activities beyond standalone hyaluronidase sales and should not be interpreted as market share.

Other Important Companies in the Hyaluronidase Market

• Amphastar Pharmaceuticals, Inc.: Manufactures Amphadase, an FDA-approved bovine-derived hyaluronidase injection used to enhance drug absorption, dispersion, and subcutaneous fluid administration.

• F. Hoffmann-La Roche Ltd.: Commercializes hyaluronidase-containing subcutaneous oncology medicines, including Phesgo and Tecentriq Hybreza, expanding enzyme applications in cancer treatment.

• Johnson & Johnson: Commercializes Darzalex Faspro and Rybrevant Faspro through its pharmaceutical business, utilizing hyaluronidase-enabled subcutaneous delivery for hematologic and solid-tumor treatments.

• Alteogen: Develops the proprietary Hybrozyme ALT-B4 recombinant hyaluronidase platform, used in Keytruda Qlex, providing an alternative technology for converting intravenous biologics into subcutaneous medicines.

 

Analyst Commentary: How Will Subcutaneous Biologics and Recombinant Enzymes Shape Market Opportunities?

The Hyaluronidase Market presents significant opportunities in recombinant enzyme technologies and subcutaneous biologic drug delivery. Increasing adoption of hyaluronidase-enabled oncology treatments, expansion of FDA-approved injectable formulations, and wider applications in aesthetic medicine are creating new revenue opportunities. The strongest potential lies in converting intravenous therapies into subcutaneous formulations, reducing administration time, improving treatment convenience, and expanding access to specialized therapies.

 

Hyaluronidase Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.23 Billion
Revenue Forecast in 2032	USD 2.25 Billion
Overall Growth Rate	CAGR of 9.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By Formulation, By End User, By Geography
By Product Type	Animal-Derived Hyaluronidase, Recombinant Human Hyaluronidase, Microbial-Derived Hyaluronidase
By Application	Drug Delivery, Dermatology and Aesthetics, Ophthalmology, Anesthesia, Oncology
By Formulation	Injectable Solutions, Lyophilized Powder, Co-formulated Injectables
By End User	Hospitals, Specialty Clinics, Aesthetic Clinics, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expanding adoption of hyaluronidase-enabled subcutaneous biologics, increasing recombinant enzyme integration in pharmaceutical formulations, wider use in dermal filler correction, expanding approvals for hyaluronidase-containing oncology therapies
Customization Option	Available upon request